Cell>Point reports promising findings for 99mTc-EC-G

04/10/2013 | AuntMinnie.com (free registration)

Radiopharmaceutical firm Cell>Point said findings from Phase I and IIa trials were promising for its technetium-99m-labeled ethylenedicysteine-glucosamine, an imaging agent used in diagnosing coronary artery disease. The company is planning a Phase IIb study to assess the diagnostic accuracy of the agent in identifying ischemia in patients at rest who have coronary artery disease.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC